Mangalam Drugs & Organics Limited (MANGALAM.NS)
INR 75.25
(2.63%)
INR 75.25
(2.63%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 133.54 Million INR | -47.64% |
| 2022 | 255.05 Million INR | -15.87% |
| 2021 | 303.17 Million INR | 201.18% |
| 2020 | 100.66 Million INR | 102.4% |
| 2019 | 49.73 Million INR | -42.14% |
| 2018 | 85.95 Million INR | -22.88% |
| 2017 | 111.46 Million INR | -46.25% |
| 2016 | 207.35 Million INR | 22.54% |
| 2015 | 169.21 Million INR | -57.02% |
| 2014 | 393.7 Million INR | -2.07% |
| 2013 | 402.02 Million INR | -9.12% |
| 2012 | 442.35 Million INR | 101.47% |
| 2011 | 219.56 Million INR | -57.17% |
| 2010 | 512.61 Million INR | 27.42% |
| 2009 | 402.28 Million INR | 10.36% |
| 2008 | 364.52 Million INR | 26.9% |
| 2007 | 287.24 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 133.54 Million INR | 0.0% |
| 2023 Q2 | 244.06 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 133.54 Million INR | -47.64% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 255.05 Million INR | -15.87% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 250.66 Million INR | 0.0% |
| 2022 Q4 | 255.05 Million INR | 0.0% |
| 2021 Q2 | 301.57 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 303.17 Million INR | 201.18% |
| 2021 Q4 | 303.17 Million INR | 0.0% |
| 2020 Q4 | 100.66 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 71.13 Million INR | 0.0% |
| 2020 FY | 100.66 Million INR | 102.4% |
| 2019 FY | 49.73 Million INR | -42.14% |
| 2019 Q4 | 49.73 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 82.36 Million INR | 0.0% |
| 2018 Q4 | 85.95 Million INR | 0.0% |
| 2018 FY | 85.95 Million INR | -22.88% |
| 2018 Q2 | 92.75 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 111.46 Million INR | -46.25% |
| 2017 Q4 | 111.46 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 189.87 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 207.35 Million INR | 22.54% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 166.78 Million INR | 0.0% |
| 2016 Q4 | 207.35 Million INR | 0.0% |
| 2015 Q4 | 169.21 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 235.54 Million INR | 0.0% |
| 2015 FY | 169.21 Million INR | -57.02% |
| 2014 Q4 | 393.7 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 393.7 Million INR | -2.07% |
| 2014 Q2 | 403.92 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 402.02 Million INR | -9.12% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 447.8 Million INR | 0.0% |
| 2013 Q4 | 402.02 Million INR | 0.0% |
| 2012 FY | 442.35 Million INR | 101.47% |
| 2012 Q4 | 442.35 Million INR | 0.0% |
| 2011 Q4 | 219.56 Million INR | 0.0% |
| 2011 FY | 219.56 Million INR | -57.17% |
| 2010 FY | 512.61 Million INR | 27.42% |
| 2009 FY | 402.28 Million INR | 10.36% |
| 2008 FY | 364.52 Million INR | 26.9% |
| 2007 FY | 287.24 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aarti Drugs Limited | 2.75 Billion INR | 95.15% |
| Albert David Limited | 6.01 Million INR | -2119.764% |
| Alembic Limited | 73.9 Million INR | -80.705% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Hester Biosciences Limited | 1.81 Billion INR | 92.653% |
| Hikal Limited | 4.22 Billion INR | 96.842% |
| Ind-Swift Limited | 10.09 Billion INR | 98.677% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Unichem Laboratories Limited | 382.22 Million INR | 65.062% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 78.763% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | -24.187% |
| Bajaj HealthCare Limited | 650.34 Million INR | 79.466% |
| Brooks Laboratories Limited | 3.56 Million INR | -3645.891% |
| Eris Lifesciences Limited | 6.54 Billion INR | 97.96% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | 88.629% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -76.712% |
| Wanbury Limited | 820 Million INR | 83.715% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -33285.25% |
| Alkem Laboratories Limited | 400 Million INR | 66.615% |
| FDC Limited | 2.46 Million INR | -5315.288% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 9.531% |
| Gufic Biosciences Limited | 1.53 Billion INR | 91.326% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -19.633% |
| Innova Captab Limited | 2.1 Billion INR | 93.657% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ipca Laboratories Limited | 5.8 Billion INR | 97.699% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.578% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Lupin Limited | 1.55 Billion INR | 91.4% |
| Medico Remedies Limited | 8.67 Million INR | -1439.91% |
| Morepen Laboratories Limited | 33.64 Million INR | -296.971% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 90.482% |
| Orchid Pharma Limited | 1.2 Billion INR | 88.911% |
| Procter & Gamble Health Limited | 68.8 Million INR | -94.1% |
| RPG Life Sciences Limited | -30.3 Million INR | 540.729% |
| Sigachi Industries Limited | 265.79 Million INR | 49.758% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -904.068% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 37.115% |
| Themis Medicare Limited | 267.74 Million INR | 50.123% |
| Vaishali Pharma Limited | 35.98 Million INR | -271.122% |
| Venus Remedies Limited | 386.8 Million INR | 65.475% |
| Windlas Biotech Limited | 20.18 Million INR | -561.749% |
| ZIM Laboratories Limited | 356 Million INR | 62.489% |
| Sakar Healthcare Limited | 549.55 Million INR | 75.7% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.374% |
| Divi's Laboratories Limited | 20 Million INR | -567.705% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -379.742% |
| Mankind Pharma Limited | 325.81 Million INR | 59.013% |
| Sequent Scientific Limited | 1.42 Billion INR | 90.643% |
| Laurus Labs Limited | 7.98 Billion INR | 98.327% |
| Neuland Laboratories Limited | 449.2 Million INR | 70.272% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 43.511% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 91.197% |
| Zydus Lifesciences Limited | 251 Million INR | 46.796% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -856.05% |
| Wockhardt Limited | 8.91 Billion INR | 98.501% |
| Bal Pharma Limited | 363.82 Million INR | 63.295% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 97.771% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 62.48% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -1351.533% |
| Shilpa Medicare Limited | 5.6 Billion INR | 97.616% |
| Valiant Laboratories Limited | 750.89 Million INR | 82.216% |
| Ajanta Pharma Limited | 235.2 Million INR | 43.222% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -314.161% |
| Granules India Limited | 689.71 Million INR | 80.638% |
| Medicamen Biotech Limited | 12.55 Million INR | -963.648% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 11054.963% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.975% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.167% |
| NATCO Pharma Limited | 53 Million INR | -151.964% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 92.723% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.011% |
| Indoco Remedies Limited | 3.51 Billion INR | 96.203% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -25.273% |